600
Participants
Start Date
August 28, 2018
Primary Completion Date
March 25, 2019
Study Completion Date
June 30, 2019
Montelukast 10mg
Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis. Montelukast should be taken once daily in the evening
Dr. Faisal Faiyaz Zuberi, Karachi
Lead Sponsor
Clinision
OTHER